FindTrial
Sign In

Prevention of dialysate-induced peritoneal damage by pyridoxal phosphate

Prevention of dialysate-induced peritoneal damage by pyridoxal phosphate - Prevention of dialysate-induced peritoneal damage by pyridoxal phosphate

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001287
Enrollment
40
Registered
2008-08-04
Start date
2009-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with end-stage renal disease on peritoneal dialysis

Interventions

Group I
Patients treated with glucose-based dialysate, to whom PLP is not given (n=20). Group II
Patients treated with glucose-based dialysate, to whom PLP is given (300mg/day, n=20)

Sponsors

Miyanomori Memorial Hospital
Lead Sponsor
Nikko Memorial Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1, Patients who are aged above 18 2, Patients with chronic renal failure on peritoneal dialysis 3, Fully informed consent should be obtained

Exclusion criteria

Exclusion criteria: 1, Patients with heart failure of NYHAIII and IV

Design outcomes

Primary

MeasureTime frame
After starting PLP treatment, the concentrations of growth factors, chemical mediators and AGE in used dialysate will be regularly measured and those indices will be compared between dialysate before and after PLP treatment.—

Secondary

MeasureTime frame
An appropriate daily dosage of PLP will be determined.—

Countries

Japan

Contacts

Public ContactSakurako Nakamura

Miyanomori Memorial Hospital Clinical nephrology

s.nakamura@miyanomori.or.jp011-641-6641

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026